BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study
Phase 3
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2013-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 468
- Registration Number
- NCT00185211
Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).
Phase 3
Completed
- Conditions
- Menopause
- Interventions
- Drug: LNG IUS
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 394
- Registration Number
- NCT00185458
Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)
Phase 2
Completed
- Conditions
- Contraception
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 742
- Registration Number
- NCT00185380
Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive
Phase 2
Completed
- Conditions
- Contraception
- Interventions
- Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K)Drug: SH D00264A (Triquilar)
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2011-07-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 58
- Registration Number
- NCT00185224
- Locations
- 🇩🇪
Bayer Schering Pharma AG - Clin. Pharm. Berlin, Berlin, Germany
Comparative Cycle Control Europe
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K)Drug: SH D 593 B (Miranova)
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2011-07-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 798
- Registration Number
- NCT00185367
- Locations
- 🇫🇷
Dr. Gwendoline Servan, Tarare, France
🇨🇿Provozorna Gynekologicka ordinace Dr. Tesar, Praha 10, Czech Republic
🇫🇷Dr. Jocelyne Nataf-Maurin, Brignoles, France
Study to Investigate Efficacy and Safety of a New Oral Contraceptive
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658K)
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2011-07-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1392
- Registration Number
- NCT00185289
- Locations
- 🇦🇹
Dr. Michaela Boeckl, Salzburg, Austria
🇩🇪Praxis Fr. Dr. J. Tyagi, Mühlheim, Hessen, Germany
🇦🇹Praxis Dr. Langer, Fuerstenfeld, Steiermark, Austria
A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2009-01-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 842
- Registration Number
- NCT00185419
Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy
Phase 2
Completed
- Conditions
- CardiomyopathiesHeart Diseases
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 138
- Registration Number
- NCT00185250
Efficacy and Tolerability of Angeliq in Thai Women
Phase 4
Completed
- Conditions
- Postmenopause
- Interventions
- Drug: Estradiol/DRSP (Angeliq, BAY86-4891)
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 55
- Registration Number
- NCT00185328
Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy
Phase 3
Completed
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Biological: Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)Other: no treatment
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-12-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 414
- Registration Number
- NCT00185393
© Copyright 2025. All Rights Reserved by MedPath